

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1-71 (canceled)

72. (Amended) A method of treating or preventing an inflammation related cardiovascular disorder in a subject in need of such treatment or prevention, comprising administering to said subject a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist compound **that produces no substantial diuretic or anti-hypertensive effect in the subject.**

73. (Previously presented) The method of claim 72 wherein said cardiovascular disorder is selected from the group consisting of: coronary artery disease; aneurysm; arteriosclerosis; atherosclerosis; myocardial infarction; embolism; stroke; thrombosis; angina; vascular plaque inflammation; vascular plaque rupture; Kawasaki disease; and calcification.

74. (Previously presented) The method of claim 73 wherein said cardiovascular disorder is myocardial infarction.

75. (Amended) The method of claim 72 wherein said epoxy-steroidal compound is selected from the group consisting of:
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, (γ-lactone, methyl ester, (7α,11α,17α)- (eplerenone);
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-dimethyl ester, (7α,11α,17α)-;
3'H-cyclopropa[6,7] pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, (γ-lactone, (6β,7β,11β,17β)-;

Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, 7-(1-methylethyl) ester, monopotassium salt, (7 α ,11 α ,17 α)-;

Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-methyl ester, monopotassium salt, (7 α ,11 α ,17 α)-;

3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, (γ -lactone, (6 α ,7 α ,11 α)-;

3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, (6 α ,7 α ,11 α ,17 α)-;

3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6 α ,7 α ,11 α ,17 α)-;

3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, (γ -lactone, (6 α ,7 α ,11 α ,17 α)-;

Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, (γ -lactone, ethyl ester, (7 α ,11 α ,17 α)-; and

Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, (γ -lactone, 1-methylethyl ester, (7 α , 11 α , 17 α)-.

76. (Previously presented) The method of Claim 75 wherein said epoxy-steroidal aldosterone receptor antagonist compound is eplerenone.

77. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-dimethyl ester, (7 α ,11 α , 17 α)-.

78. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7] pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ -lactone, (6 β ,7 β ,11 β ,17 β)-.

79. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, 7-(1-

methylethyl) ester, monopotassium salt, (7 α ,11 α ,17 α)-.

80. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-methyl ester, monopotassium salt, (7 α ,11 α ,17 α)-.

81. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ -lactone, (6 α ,7 α ,11 α ,)-.

82. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, (6 α ,7 α ,11 α ,17 α)-.

83. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6 α ,7 α ,11 α ,17 α)-.

84. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ -lactone, (6 α ,7 α ,11 α ,17 α)-.

85. (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ -lactone, ethyl ester, (7 α ,11 α ,17 α)-.

86. (withdrawn) The method of claim 75 wherein said Aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ -lactone, ethyl ester, (7 α ,11 α ,17 α)-.

87-90 (canceled)

91. (Previously presented) The method of Claim 75 wherein the therapeutically-effective amount of epoxy-steroidal compound administered is between about 0.5 to about 10 mg per day.

92-95 (canceled)

96. (Previously presented) The method of Claim 76 wherein the therapeutically-effective amount of epoxy-steroidal compound administered is between about 0.5 to about 10 mg per day.